Paul Chamberlain, CooperVision Senior Director of Research Programs (IMAGE)
Caption
During the 2022 International Myopia Conference, Paul Chamberlain, CooperVision Senior Director of Research Programs, will offer new insights into the treatment efficacy of the fastest growing eyes fit with MiSight® 1 day contact lenses, derived from the world’s longest-running soft contact lens study among children. The international seven-year MiSight® 1 day clinical trial has become the gold standard for evaluating myopia control effectiveness because of its robust design, multi-country enrollment, and extent of professionally published and peer-reviewed data.
Credit
CooperVision
Usage Restrictions
None
License
Original content